SU-DHL-10 人彌漫大B
- 公司名稱 上海富雨生物科技有限公司
- 品牌
- 型號(hào)
- 產(chǎn)地
- 廠商性質(zhì) 生產(chǎn)廠家
- 更新時(shí)間 2025/2/11 15:24:41
- 訪問(wèn)次數(shù) 32
聯(lián)系方式：陳壽彬18956075901 查看聯(lián)系方式
聯(lián)系我們時(shí)請(qǐng)說(shuō)明是化工儀器網(wǎng)上看到的信息，謝謝!
產(chǎn)品名稱：SU-DHL-10 人彌漫大B細(xì)胞淋巴瘤細(xì)胞、SU-DHL-10 人彌漫大B細(xì)胞淋巴瘤細(xì)胞、SU-DHL-10 人彌漫大B細(xì)胞淋巴瘤細(xì)胞、SU-DHL-10 人彌漫大B細(xì)胞淋巴瘤細(xì)胞；
| 種屬 | 人 |
| 別稱 | Su-DHL-10; SUDHL10; Sudhl10; SUDHL-10; SuDHL 10; Stanford University-Diffuse Histiocytic Lymphoma-10; DHL10 |
| 組織來(lái)源 | 淋巴結(jié) |
| 疾病 | 大細(xì)胞淋巴瘤 |
| 傳代比例/細(xì)胞消化 | 1：2傳代 |
| 培養(yǎng)基配置 | RPMI1640 培養(yǎng)基；10%胎牛血清；1%雙抗 |
| 簡(jiǎn)介 | established from the pleural effusion of a 25-year-old man with B-cell non-Hodgkin lymphoma (B- NHL), described at the time as diffuse histiocytic lymphoma; cell line carries EZH2 Y641F mutation (own results); assigned to GCB-like lymphoma subtype (germinal center B-cell) |
| 形態(tài) | 淋巴母細(xì)胞樣 |
| 生長(zhǎng)特征 | 懸浮生長(zhǎng) |
| 倍增時(shí)間 | ~40h |
| STR | D5S818: 11, 12 D13S317: 10, 11 D7S820: 8, 11 D16S539: 10, 11 vWA: 17 THO1: 8, 9.3 TPOX: 8 CSF1PO: 10, 13 Amelogenin: XYTPOX: 8 CSF1PO: 10, 13 |
| 培養(yǎng)條件 | 氣相 ：空氣 ，95% ；二氧化碳 ，5%。 溫度 ：37攝氏度 ，培養(yǎng)箱濕度為70%-80%。 |
| 凍存條件 | 凍存液 ：90%FBS ，DMSO 10%, 或使用非程序凍存液 ：貨號(hào)JY-H040 |
| 保藏機(jī)構(gòu) | ATCC; CRL-2963 |
| 備注 | 該細(xì)胞為懸浮細(xì)胞 ，請(qǐng)注意離心收集細(xì)胞懸液 ，請(qǐng)勿直接倒掉細(xì)胞培養(yǎng)液。 |
| 產(chǎn)品使用 | 于科學(xué)研究 ，不可作為動(dòng)物或人類疾病的治療產(chǎn)品使用。 |
with fewer side effects, and with better therapeutic results. In addition, medicines that target tau proteins in addition to Aβ are in the works. Early intervention, based on precise biomarkers, is a linchpin of Alzheimers care, emphasizing the critical need for detecting the disease at its earliest stages. Lifestyle interventions, encompassing diet, exercise, cognitive training, and social engagement, are emerging as key components in the fight against cognitive decline. Data analytics and art are gaining prominence as strategies to mitigate the brains inflammatory responses. To pool knowledge and resources in the fight against Alzheimers, international cooperation between scientists, doctors, and pharmaceutical companies is still essential. In essence, a complex, individualized, and collaborative strategy will characterize Alzheimers research and therapy in the future. Despite obstacles, these encouraging possibilities show the ongoing commitment of the scientific and medical communities to combat A.D. head-on, providing a glimmer of hope to the countless people and families touched by this savage sickness.
采購(gòu)中心
化工儀器網(wǎng)